These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 11445737)

  • 1. Activated protein C versus protein C in severe sepsis.
    Yan SB; Dhainaut JF
    Crit Care Med; 2001 Jul; 29(7 Suppl):S69-74. PubMed ID: 11445737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous protein C activation in patients with severe sepsis.
    Liaw PC
    Crit Care Med; 2004 May; 32(5 Suppl):S214-8. PubMed ID: 15118520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated).
    Macias WL; Yan SB; Williams MD; Um SL; Sandusky GE; Ballard DW; Planquois JM
    Crit Care; 2005; 9 Suppl 4(Suppl 4):S38-45. PubMed ID: 16168074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis.
    Dhainaut JF; Yan SB; Cariou A; Mira JP
    Crit Care Med; 2002 May; 30(5 Suppl):S318-24. PubMed ID: 12004254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coagulation in severe sepsis: a central role for thrombomodulin and activated protein C.
    Faust SN; Heyderman RS; Levin M
    Crit Care Med; 2001 Jul; 29(7 Suppl):S62-7; discussion S67-8. PubMed ID: 11445736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein C in critical illness.
    Mann HJ; Short MA; Schlichting DE
    Am J Health Syst Pharm; 2009 Jun; 66(12):1089-96. PubMed ID: 19498123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis.
    Grinnell BW; Joyce D
    Crit Care Med; 2001 Jul; 29(7 Suppl):S53-60; discussion S60-1. PubMed ID: 11445735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human activated protein C in severe sepsis.
    Mann HJ
    Am J Health Syst Pharm; 2002 Feb; 59 Suppl 1():S19-23. PubMed ID: 11885409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation.
    Esmon CT
    Crit Care Med; 2001 Jul; 29(7 Suppl):S48-51; discussion 51-2. PubMed ID: 11445734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New and emerging therapies for sepsis.
    Healy DP
    Ann Pharmacother; 2002 Apr; 36(4):648-54. PubMed ID: 11918516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein C/activated protein C pathway: overview of clinical trial results in severe sepsis.
    Dhainaut JF; Yan SB; Claessens YE
    Crit Care Med; 2004 May; 32(5 Suppl):S194-201. PubMed ID: 15118517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukocyte and endothelial cell interactions in sepsis: relevance of the protein C pathway.
    Joyce DE; Nelson DR; Grinnell BW
    Crit Care Med; 2004 May; 32(5 Suppl):S280-6. PubMed ID: 15118531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis.
    Bernard GR
    Crit Care Med; 2003 Jan; 31(1 Suppl):S85-93. PubMed ID: 12544981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.
    Barton P; Kalil AC; Nadel S; Goldstein B; Okhuysen-Cawley R; Brilli RJ; Takano JS; Martin LD; Quint P; Yeh TS; Dalton HJ; Gessouron MR; Brown KE; Betts H; Levin M; Macias WL; Small DS; Wyss VL; Bates BM; Utterback BG; Giroir BP
    Pediatrics; 2004 Jan; 113(1 Pt 1):7-17. PubMed ID: 14702440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated protein C and sepsis.
    O'Brien LA; Gupta A; Grinnell BW
    Front Biosci; 2006 Jan; 11():676-98. PubMed ID: 16146761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.
    De Backer D
    Drug Saf; 2007; 30(11):995-1010. PubMed ID: 17973539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet factor 4 modulation of the thrombomodulin-protein C system.
    Slungaard A
    Crit Care Med; 2004 May; 32(5 Suppl):S331-5. PubMed ID: 15118540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated protein C: potential therapy for severe sepsis, thrombosis, and stroke.
    Griffin JH; Zlokovic B; Fernández JA
    Semin Hematol; 2002 Jul; 39(3):197-205. PubMed ID: 12124682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microvascular endothelial dysfunction: a renewed appreciation of sepsis pathophysiology.
    Vincent JL
    Crit Care; 2001; 5(2):S1-5. PubMed ID: 11379985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated protein C modulates chemokine response and tissue injury in experimental sepsis.
    Sharma GR; Gerlitz B; Berg DT; Cramer MS; Jakubowski JA; Galbreath EJ; Heuer JG; Grinnell BW
    Adv Exp Med Biol; 2008; 614():83-91. PubMed ID: 18290317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.